公开(公告)号：US11964978B2

公开(公告)日：2024-04-23

申请号：US17693197

申请日：2022-03-11

Applicant: PFIZER INC.

Inventor： Ketan Satish Gajiwala ,  Chan Woo Huh ,  Mehran Jalaie ,  Ryan Lloyd Patman ,  Eugene Yuanjin Rui ,  Jianmin Sun ,  Martin James Wythes

IPC: C07D487/04 ,  A61K31/437 ,  A61K31/519 ,  A61P35/00 ,  C07D471/04

CPC classification number: C07D487/04 ,  C07D471/04

Abstract: Provided herein are compounds of the general formula (I):




and pharmaceutically acceptable salts thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

公开(公告)号：US20240336572A1

公开(公告)日：2024-10-10

申请号：US18626467

申请日：2024-04-04

Applicant: Pfizer Inc.

Inventor： Samit Kumar Bhattacharya ,  Edward Lee Conn ,  David Christopher Ebner ,  Brian Stephen Gerstenberger ,  Chan Woo Huh ,  Daniel Wei-Shung Kung ,  Alan Martin Mathiowetz ,  Jessica Gloria Katherine O'Brien ,  Meihua Mike Tu ,  Kimberly O'Keefe Cameron ,  Dilinie Prasadhini Fernando ,  Kevin James Filipski ,  Esther Cheng Yin Lee ,  Sarah Jane Mear ,  Aaron Christopher Smith

IPC: C07D231/56 ,  A61K31/416

CPC classification number: C07D231/56 ,  A61K31/416

Abstract: The invention relates to substituted indazole propionic acid derivatives, pharmaceutically acceptable salts, tautomers, or pharmaceutically acceptable salts of the tautomers thereof that can activate adenosine 5′-monophosphate-activated protein kinase (AMPK). The invention further relates to pharmaceutical compositions comprising AMPK-activating substituted indazole propionic acid derivatives, pharmaceutically acceptable salts, tautomers, or pharmaceutically acceptable salts of the tautomers thereof and at least one pharmaceutically acceptable excipient, and methods of treating a condition comprising administering AMPK-activating substituted indazole propionic acid derivatives, pharmaceutically acceptable salts, tautomers, or pharmaceutically acceptable salts of the tautomers thereof.